###begin article-title 0
Zfra affects TNF-mediated cell death by interacting with death domain protein TRADD and negatively regulates the activation of NF-kappaB, JNK1, p53 and WOX1 during stress response
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 279 280 279 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
Zfra is a 31-amino-acid zinc finger-like protein, which is known to regulate cell death by tumor necrosis factor (TNF) and overexpressed TNF receptor- or Fas-associated death domain proteins (TRADD and FADD). In addition, Zfra undergoes self-association and interacts with c-Jun N-terminal kinase 1 (JNK1) in response to stress stimuli. To further delineate the functional properties of Zfra, here we investigated Zfra regulation of the activation of p53, WOX1 (WWOX or FOR), NF-kappaB, and JNK1 under apoptotic stress.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 406 411 <span type="species:ncbi:4932">yeast</span>
Transiently overexpressed Zfra caused growth suppression and apoptotic death of many but not all types of cells. Zfra either enhanced or blocked cell death caused by TRADD, FADD, or receptor-interacting protein (RIP) in a dose-related manner. This modulation is related with Zfra binding with TRADD, NF-kappaB, JNK1 and WOX1, as determined by GST pull-down analysis, co-immunoprecipitation, and mapping by yeast two-hybrid analysis. Functionally, transiently overexpressed Zfra sequestered NF-kappaB (p65), WOX1, p53 and phospho-ERK (extracellular signal-activated kinase) in the cytoplasm, and TNF or UV light could not effectively induce nuclear translocation of these proteins. Zfra counteracted the apoptotic functions of Tyr33-phosphorylated WOX1 and Ser46-phosphorylated p53. Alteration of Ser8 to Gly abolished the apoptotic function of Zfra and its regulation of WOX1 and p53.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
In response to TNF, Zfra is upregulated and modulates TNF-mediated cell death via interacting with TRADD, FADD and RIP (death-inducing signaling complex) at the receptor level, and downstream effectors NF-kappaB, p53, WOX1, and JNK1.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 6 18 6 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WWOX/FRA16D </italic>
###xml 128 129 128 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 130 131 130 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 196 197 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 234 239 234 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WWOX </italic>
###xml 289 290 289 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 291 292 291 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 333 334 333 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 467 468 467 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 536 541 536 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WWOX </italic>
###xml 678 679 678 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 729 730 729 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human WWOX/FRA16D gene encodes a candidate tumor suppressor WW domain-containing oxidoreductase, designated WWOX, FOR, or WOX1 [1-3]. This gene is located on a common fragile site ch16q23.3-24.1 [1,2]. Loss of heterozygosity (LOH) of WWOX gene has been found in several types of cancers [[4,5]; reviews]. WWOX/FOR/WOX1 possesses two N-terminal WW domains (containing conserved tryptophan residues), a nuclear localization sequence (NLS) between the WW domains, and a C-terminal short chain alcohol dehydrogenase/reductase (SDR) domain. WWOX mRNA may undergo alternative splicing, thereby generating at least 8 mRNAs mainly coding for proteins with altered SDR domain sequences [4]. Several protein isoforms have been identified [4]. Nonetheless, presence of specific protein isoforms in normal and cancerous tissues remains to be established.
###end p 9
###begin p 10
###xml 98 106 98 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 135 136 135 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 310 311 310 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 312 313 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 314 315 314 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 468 469 468 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 470 471 470 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 472 473 472 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 664 665 664 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 666 667 666 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 668 669 668 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 813 814 813 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 300 303 <span type="species:ncbi:10116">rat</span>
WWOX/FOR/WOX1 is considered as a candidate tumor suppressor and proapoptotic protein, whereas its in vivo function is largely unknown [4]. Under stress conditions, WOX1 undergoes phosphorylation at Tyr33 and may translocate to the mitochondria and nuclei to induce apoptosis in cultured cells and in rat eyes [3,6-9]. Tyr33-phosphorylated or activated WOX1 binds to the proline-rich region and phospho-Ser46 of p53, and both proteins induce apoptosis synergistically [3,6,8]. When WOX1 is functionally suppressed by antisense mRNA, small interfering RNA (siRNA), or dominant negatives, the stability of p53 and its apoptotic function are significantly suppressed [3,6,8]. The proapoptotic function of WOX1 is probably associated, in part, with its interaction with p53, p73, JNK1 and other transcription factors [4].
###end p 10
###begin p 11
###xml 80 81 80 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 82 83 82 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 84 85 84 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 589 591 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 754 756 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 39 44 <span type="species:ncbi:4932">yeast</span>
To isolate WOX1-binding proteins using yeast two-hybrid cDNA library screening [3,6,8], we found that WOX1 interacts with a small size 31-amino-acid protein, Zfra (zinc finger-like peptide that regulates apoptosis) [10]. Zfra belongs to the family of C2H2 type zinc finger proteins [11-13], and has a sequence homology to transcription factor forkhead protein xFKHR1 [14]. Zinc finger proteins interact with DNA and RNA, which is essential for regulating gene transcription during cell growth and embryogenesis. Damage to the zinc fingers in DNA repair proteins may induce carcinogenesis [15]. Zfra mRNA is expressed in many organs and tissues and most abundant in the spleen [10]. However, it is absent in several prostate and breast cancer cell lines [10].
###end p 11
###begin p 12
###xml 86 88 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 89 91 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 203 205 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 455 457 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 653 655 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 710 712 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 713 715 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
Zfra participates in the signal pathway of tumor necrosis factor (TNF or TNF-alpha) [[16,17]; reviews]. Zfra appears to play a dual role in regulating the cytotoxic effects of TNF and Fas ligand (FasL) [10]. Zfra either enhances or blocks the apoptotic functions of transiently overexpressed receptor adaptor proteins TRADD (tumor necrosis factor receptor type 1-associated death domain protein) and FADD (Fas-associated death domain-containing protein) [10]. TRADD and FADD are recruited to the TNF receptors when cells are stimulated with TNF or Fas ligand (FasL). In response to TNF and UV light, Zfra undergoes self-binding and interacts with JNK1 [10]. JNK1 is a downstream effector of the TNF signaling [18-20]. The functional mechanism for the action of Zfra remains to be established.
###end p 12
###begin p 13
###xml 570 579 566 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 583 590 579 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
In this study, we further investigated the underlying mechanisms for the regulatory effect of Zfra on cell death caused by transiently overexpressed death domain proteins, including TRADD, FADD and RIP (receptor-interacting protein). We determined the role of a conserved phosphorylation site at serine 8 in conferring Zfra-induced apoptosis. Also, we examined whether Zfra regulates the activation of transcription factor NF-kappaB and tumor suppressors p53 and WOX1 in response to TNF and UV light, and discussed the biological implications of their interactions both in vitro and in vivo.
###end p 13
###begin title 14
Results
###end title 14
###begin title 15
Transiently overexpressed Zfra induces apoptosis
###end title 15
###begin p 16
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
We have previously shown that when ectopic Zfra is stably expressed in L929 fibroblasts, these cells resist the cytotoxic effects of TNF and FasL [10]. In contrast, depending upon the concentrations used or the extent of expression, transiently expressed Zfra could either enhance or inhibit the cytotoxic function of overexpressed death domain proteins TRADD and FADD [10]. The underlying mechanism of this regard is unknown.
###end p 16
###begin p 17
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 562 564 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 705 707 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 930 932 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 1120 1122 1120 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 376 381 <span type="species:ncbi:9606">human</span>
###xml 530 536 <span type="species:ncbi:10090">murine</span>
###xml 598 603 <span type="species:ncbi:9606">human</span>
###xml 623 627 <span type="species:ncbi:452646|species:ncbi:9666">mink</span>
To further examine the role of Zfra-mediated death, a panel of adherent cell lines was transfected with an EGFP-tagged Zfra cDNA expression construct by CaPO4. For non-adherent Molt4 T cells, the DNA construct was introduced by electroporation (Figure 1A). In controls, cells were transfected with buffer or EGFP vector only. Following 48 hr in culture, Zfra induced death of human cell lines including ovarian ME180, embryonic kidney HEK-293, neuroblastoma SK-N-SH, Molt4 T lymphocytes, and breast MCF7 and MDA-MB-231 cells, and murine L929 fibroblasts (Figure 1A). However, Zfra had no effect on human prostate DU145 and mink lung epithelial Mv1Lu cells (Figure 1A). Based on our previous observations [10], an optimal dose of Zfra, 150 ng/well in 96-well plates, was used to produce ~30-40% death of L929 cells. Cells with positive protein expression were approximately 60-75%, as determined by fluorescence microscopy (Figure 1A). EGFP-Zfra was present ubiquitously in cell compartments in majority of the tested cells. Interestingly, EGFP-Zfra was mainly present in the cytoplasm in breast MDA-MB-231 cells (Figure 1A).
###end p 17
###begin p 18
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Zfra induces apoptotic cell death</bold>
###xml 36 37 36 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 605 607 603 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1300 1301 1298 1299 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1467 1469 1465 1467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1585 1586 1583 1584 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 87 92 <span type="species:ncbi:9606">human</span>
###xml 215 221 <span type="species:ncbi:10090">murine</span>
###xml 248 253 <span type="species:ncbi:9606">human</span>
###xml 273 277 <span type="species:ncbi:452646|species:ncbi:9666">mink</span>
Zfra induces apoptotic cell death. (A) Transiently overexpressed Zfra induced death of human ovarian ME180, embryonic kidney HEK-293, neuroblastoma SK-N-SH, breast MDA-MB-231 and MCF7 cells, Molt4 T lymphocytes and murine L929 fibroblasts, but not human prostate DU145 and mink lung epithelial Mv1Lu cells. These cells were transfected with an EGFP (vector) or EGFP-Zfra expression vector (150 ng/well in 96-well microtiter plates) or medium (control) by CaPO4, followed by culturing for 48 hr and then staining with crystal violet for determining the extent of death (n = 8; mean +/- standard deviation; p < 0.001, EGFP vector-transfected cells versus EGFP-Zfra-transfected cells except DU145 and Mv1Lu; Student's t tests). Molt4 T cells were transfected with the DNA constructs by electroporation. Data shown in the buffer and vector (EGFP) controls are from testing L929 cells. Similar data were obtained using other cells. The numbers of cells with positive EGFP or EGFP-Zfra protein expression were ~60-75%, as determined by fluorescence microscopy. EGFP-Zfra was present ubiquitously in cell compartments in majority of the tested cells (see representative L929 cells; 200x magnification). Interestingly, EGFP-Zfra was mainly present in the cytoplasm of MDA-MB-231 cells (400x magnification). (B) In adherence- or anchorage-independent growth assay on agarose, Zfra was shown to block colony formation of L929 cells, as opposed to empty vector controls (n = 3, p < 0.001; Student's t test). Live colonies were stained with a soluble tetrazolium-based MTS proliferation reagent. (C) Molt4 T cells were electroporated with the EGFP-Zfra expression vector, followed by culturing for 48 hr and analyzing the extent of apoptosis using Annexin V assay.
###end p 18
###begin p 19
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
Cells, including HEK-293, SK-N-SH, Molt4 and L929, express Zfra mRNA, and they are sensitive to Zfra-induced death [10]. Breast MCF7 and MDA-MB-231 cells do not express Zfra [10], but were sensitive to Zfra-mediated death (Figure 1A). Prostate DU145 is a Zfra-negative cell line [10], and resisted death by Zfra (Figure 1A). Together, our data show that resistance to Zfra-mediated death is not related with the presence or absence of endogenous Zfra in cells.
###end p 19
###begin p 20
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
We examined the effect of Zfra on anchorage-independent cell growth [21]. As expected, Zfra blocked colony formation of L929 cells on agarose plates, as compared to empty vector controls (Figure 1B).
###end p 20
###begin p 21
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
To further determine Zfra-mediated apoptosis, Molt4 T cells were transfected with EGFP-Zfra and cultured for 48 hr. The extent of exposure of phosphatidylserine to cell surface was determined by Annexin V assay. Zfra increased the exposure of phosphatidylserine on cell surface (Figure 1C), indicating that cells have undergone apoptosis.
###end p 21
###begin title 22
Involvement of conserved serine 8 (Ser8) in Zfra-induced apoptosis
###end title 22
###begin p 23
###xml 50 52 50 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 507 508 503 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
Ser8 is a conserved phosphorylation site in Zfra [10]. We determined the potential role of this site in conferring the apoptotic function of Zfra. By site-directed mutagenesis, Ser8 was altered to Gly (S8G). L929 cells were electroporated with EGFP-Zfra, S8G, or EGFP, and the cells were cultured for 48 hr. Again, transiently overexpressed Zfra induced death of L929 cells (34.8 +/- 8.6%; n = 8), whereas S8G mutant had a significantly reduced activity in causing cell death (17.1 +/- 5.6%; n = 8) (Figure 2). These observations suggest that Ser8 phosphorylation is essential for Zfra-induced apoptosis.
###end p 23
###begin p 24
###xml 0 42 0 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Ser8 is involved in Zfra-induced apoptosis</bold>
###xml 441 443 437 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Ser8 is involved in Zfra-induced apoptosis. Ser8 is a conserved phosphorylation site in Zfra [10]. Ser8 was altered to Gly (S8G). L929 cells were electroporated with EGFP-Zfra, S8G, or EGFP, followed by culturing for 48 hr and staining with crystal violet. Transiently overexpressed Zfra induced death of L929 cells (34.8 +/- 8.6%; n = 8), whereas S8G mutant had a significantly reduced activity in causing cell death (17.1 +/- 5.6%; n = 8; p < 0.005, Student's t test; see *). The extent of protein expression is shown.
###end p 24
###begin title 25
Zfra regulates death domain protein-mediated cell death
###end title 25
###begin p 26
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 381 382 381 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 674 675 674 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 771 772 771 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 941 942 941 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
TRADD, FADD and RIP are recruited to the TNF receptor during TNF signaling. RIP interacts with TRADD or FADD [17]. We have shown that Zfra modulates the apoptotic function of overexpressed TRADD and FADD [10]. Here, we continued to examine whether Zfra affects RIP-mediated cell death. We used ME180, HEK-293 and DU145 cells, and DU145 was resistant to Zfra-mediated death (Figure 1). These cells were cotransfected with "cytotoxic" doses of cDNA expression constructs of TRADD and/or Zfra (tagged with EGFP) by CaPO4. Similar experiments were performed with Zfra with FADD and RIP. Both Zfra and TRADD induced death of ME180 and HEK-293 cells in an additive manner (Figure 3). Nonetheless, Zfra did not increase cell death with FADD or RIP in an additive manner (Figure 3). In the Zfra-resistant DU145 cells, Zfra alone did not cause cell death, but increased the cytotoxic function of TRADD, FADD and RIP by approximately 100-150% (Figure 3).
###end p 26
###begin p 27
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of Zfra on TRADD, FADD, or RIP-mediated cell death</bold>
###xml 418 420 418 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 566 568 566 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 793 795 793 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Effect of Zfra on TRADD, FADD, or RIP-mediated cell death. ME180, HEK-293 and DU145 cells were transfected with cytotoxic doses of TRADD, FADD, or RIP cDNA (200 ng/well), in the presence or absence of EGFP-Zfra (200 ng/well) by CaPO4. These cells were cultured for 48 hr and then stained with crystal violet. In Zfra-sensitive ME180 and HEK-293 cells, Zfra and TRADD increased cell death in an additive manner (n = 8; p < 0.001, TRADD alone versus TRADD/Zfra in combination; Student's t tests), whereas no additive effect was shown for Zfra with FADD or RIP (n = 8; p > 0.05, FADD or RIP alone versus Zfra/FADD or Zfra/RIP; Student's t tests). In Zfra-resistant DU145 cells, Zfra alone did not induce death, but enhanced the death by ectopic TRADD, FADD and RIP by ~100-150% increases (n = 8; p < 0.001; Student's t tests). EGFP-Zfra was expressed in approximately 60-70% of total cells, as visualized by fluorescence microscopy.
###end p 27
###begin p 28
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
Next, we tested the effect on death using non-cytotoxic doses of cDNA constructs. Under this condition, there was a synergistic enhancement of ME180 cell death by Zfra and TRADD, FADD or RIP (Figure 4).
###end p 28
###begin p 29
###xml 0 92 0 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Synergistic enhancement of cell death by non-cytotoxic levels of Zfra and TRADD, FADD or RIP</bold>
###xml 360 362 358 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Synergistic enhancement of cell death by non-cytotoxic levels of Zfra and TRADD, FADD or RIP. Zfra-sensitive ovarian ME-180 cells were transfected with non-cytotoxic doses of TRADD (FADD or RIP) (20, 40, 80 ng/well) and/or EGFP-Zfra by CaPO4. Zfra and TRADD, FADD, or RIP synergistically induced ME180 cell death in 48 hr (n = 16; mean +/- standard deviation; p < 0.001; Zfra, TRADD, FADD, or RIP alone versus Zfra/TRADD, Zfra/FADD, or Zfra/RIP; Student's t tests). Cells were stained with crystal violet. EGFP-Zfra was expressed in approximately 60-70% of total cells, as visualized by fluorescence microscopy.
###end p 29
###begin p 30
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
Indeed, Zfra regulates cell growth in a biphasic manner. At low doses, Zfra enhanced growth of Zfra-sensitive L929 cells. But, cell death occurred when higher doses of Zfra were used, as measured 48 hr post transfection (Figure 5A). Cytotoxic levels of RIP blocked the growth enhancement of Zfra. Similarly, at low levels RIP had no effect on L929 cell growth, and when in combination, non-toxic doses of Zfra and RIP increased the cell death (Figure 5B).
###end p 30
###begin p 31
###xml 0 47 0 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Zfra regulates cell growth in a biphasic manner</bold>
###xml 50 51 50 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 332 333 330 331 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
Zfra regulates cell growth in a biphasic manner. (A) L929 cells were transfected with various amounts of EGFP-Zfra and/or a non-toxic dose of RIP (100 ng/well) by CaPO4. Zfra alone enhanced cell growth at low doses, but induced death at higher doses (n = 8; mean +/- standard deviation). RIP blocked the Zfra-mediated cell growth. (B) Similarly, L929 cells were transfected with various amounts of RIP and/or a non-toxic dose of Zfra (60 ng/well). At low levels, RIP had little or no effect on cell growth. When in combination, both Zfra and RIP effectively increased the cell death (n = 8; mean +/- standard deviation). Cells were stained with crystal violet. EGFP-Zfra was expressed in approximately 60-70% of total cells, as visualized by fluorescence microscopy.
###end p 31
###begin p 32
Taken together from the above experiments, our data clearly show that depending upon concentrations or the extent of expression, Zfra may regulate the function of death domain proteins TRADD, FADD or RIP in a synergistic or an antagonistic manner.
###end p 32
###begin title 33
Zfra physically interacts with TRADD, and binds to the N-terminal first WW domain and C-terminal SDR domain of WOX1
###end title 33
###begin p 34
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 382 383 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 384 385 378 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 386 387 380 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 570 571 564 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 613 614 607 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 720 721 714 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 891 900 885 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 904 912 898 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 913 914 907 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 915 916 909 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 917 918 911 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 919 920 913 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 943 944 937 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1060 1061 1054 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 1186 1187 1180 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1188 1189 1182 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1190 1191 1184 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1201 1202 1195 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 187 192 <span type="species:ncbi:4932">yeast</span>
###xml 280 285 <span type="species:ncbi:4932">yeast</span>
###xml 436 441 <span type="species:ncbi:4932">yeast</span>
We have utilized a novel cytoplasm-based two-hybrid analysis in mapping protein/protein interactions between domains and/or motifs [3,6,8]. Briefly, bait is expressed in the cytoplasm of yeast cells. When the bait physically interacts with a cell membrane-anchored target, mutant yeast cells grow in a selective medium at 37degreesC as a result of activation of Ras signal pathway [3,6,8]. We showed that Zfra interacted with WOX1 from yeast two-hybrid library screening. To map the Zfra-binding domain(s) in WOX1, we determined that Zfra physically interacted with the N-terminal first WW domain of WOX1 (Figure 6). Alteration of the known phosphorylation site Tyr33 to Arg in this domain abrogated the binding (Figure 6), suggesting that Tyr33 phosphorylation is needed for WOX1 to interact with Zfra. During activation, WOX1 undergoes Tyr33 phosphorylation and nuclear translocation both in vitro and in vivo [3,6,8,9]. Zfra also bound the C-terminal SDR domain. This domain has a mitochondria-targeting region, and Zfra did not bind to this region (Figure 6). In a negative control, empty vector versus empty vector was tested. In a positive control, self-binding of MafB is shown [3,6,8] (Figure 6).
###end p 34
###begin p 35
###xml 36 37 36 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 67 68 67 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 0 96 0 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Zfra physically binds TRADD and the <italic>N</italic>-terminal first WW domain and <italic>C</italic>-terminal SDR domain in WOX1</bold>
###xml 347 348 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 382 383 376 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 177 182 <span type="species:ncbi:4932">yeast</span>
###xml 286 291 <span type="species:ncbi:4932">yeast</span>
###xml 591 595 <span type="species:ncbi:262676">Mito</span>
###xml 605 610 <span type="species:ncbi:4932">yeast</span>
Zfra physically binds TRADD and the N-terminal first WW domain and C-terminal SDR domain in WOX1. Binding of Zfra (as target) with WOX1 (as bait) was mapped by Ras rescue-based yeast two-hybrid analysis (see Materials and Methods). Positive binding is evidenced by the growth of mutant yeast at 37degreesC in a selective medium. Zfra bound to the N-terminal first WW domain and the C-terminal SRD domain of WOX1. Alteration of the known phosphorylation site Tyr33 to Arg33 (Y33R) in WOX1 abrogated the binding. Zfra did not interact with the mitochondria-targeting region in the SDR domain (Mito-SDR). No yeast cell growth at 37degreesC was shown when empty vector versus empty vector was tested as a negative control. In a positive control, the self-binding of MafB is shown. In addition, Zfra was shown to bind the full-length TRADD, but not RIP. WOX1 also bound TRADD. Neg cont: negative control; Pos cont: positive control.
###end p 35
###begin p 36
###xml 130 131 130 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
We also determined that Zfra physically interacted with the full-length TRADD but not RIP, and WOX1 interacted with TRADD (Figure 6). Together, these observations suggest that Zfra and WOX1 may complex with TRADD, and this complex affects TNF-mediated cell death.
###end p 36
###begin title 37
TNF induces the binding of Zfra with Tyr33-phosphorylated WOX1, JNK1, and NF-kappaB
###end title 37
###begin p 38
###xml 211 212 211 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 526 528 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
To verify the above observations, we utilized GST (Glutathione S-Transferase) pull-down analysis and co-immunoprecipitation to characterize the binding of Zfra with its partners. Zfra was tagged with GST at its N-terminus. Recombinant GST-Zfra protein was produced in bacteria, and then purified using glutathione-Sepharose 4B resin. Similarly, recombinant GST alone was produced and purified. Exposure of Zfra-sensitive SK-N-SH cells to TNF resulted in an increased expression of Zfra and degradation of IkappaBalpha (Figure 7A), indicating that this cell line has a functional TNF signal pathway. This cell line expresses a low level of Zfra.
###end p 38
###begin p 39
###xml 0 113 0 109 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TNF and UV light increase the binding of Zfra with WOX1, JNK1 and NF-&#954;B, but weakly with p53 in SK-N-SH cells</bold>
###xml 116 117 112 113 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 241 242 229 230 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 811 812 787 788 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 950 951 918 919 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 1006 1007 974 975 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1157 1158 1125 1126 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 1210 1211 1178 1179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
TNF and UV light increase the binding of Zfra with WOX1, JNK1 and NF-kappaB, but weakly with p53 in SK-N-SH cells. (A) Exposure of SK-N-SH cells to TNF (50 ng/ml) for 40 min resulted in upregulation of Zfra and degradation of IkappaBalpha. (B) In GST pull-down analysis using SK-N-SH cells, TNF increased the binding of GST-Zfra with NF-kappaB (p65) and JNK1 (greater than 50%), and weakly with p53 but not IkappaBalpha. GST-Zfra physically interacted with endogenous Zfra and WOX1, and TNF limitedly increased the binding (less than 30%). In negative controls, GST alone could not bind the above-indicated proteins. The relative amounts of GST and GST-Zfra used in the pull down are shown. One-twentieth amounts of protein input for endogenous Zfra and other indicated proteins are shown in Western blotting. (C) Similarly, during a 10-min treatment, TNF increased the binding of GST-Zfra with p-WOX1, but not with FADD, RIP, IkappaBalpha and Fas. (D) SK-N-SH cells were exposed to UV light (120 mJoule/cm2) and then cultured for 1 hr, followed by processing GST pull-down analysis. UV light increased the binding of endogenous Zfra with p-WOX1 and JNK1. (E) By co-immunoprecipitation, UV light (120 mJoule/cm2) increased the binding of endogenous Zfra with itself and p-JNK1 (at Thr183/Tyr185) (greater than 50% increase), but limitedly with WOX1 (less than 20% increase), in SK-N-SH cells.
###end p 39
###begin p 40
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7B</xref>
###xml 382 384 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7B</xref>
###xml 389 391 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7C</xref>
###xml 463 465 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7B</xref>
###xml 470 472 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7C</xref>
###xml 524 525 512 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 671 673 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7D</xref>
###xml 836 838 824 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7E</xref>
Zfra is able to undergo self-association and binds JNK1 [10]. In GST pull-down assays, GST-Zfra was shown to interact with endogenous Zfra and WOX1, and TNF barely increased the binding in SK-N-SH cells (Figure 7B). In addition, TNF increased the binding of GST-Zfra with JNK1, NF-kappaB (p65) and p-WOX1 (Tyr33 phosphorylated), and weakly with p53 in a time-related manner (Figure 7B and 7C). Zfra could not interact with IkappaBalpha, FADD, RIP and Fas (Figure 7B and 7C). Similarly, in response to UV light (120 mJoule/cm2), there was an increased binding of GST-Zfra with endogenous Zfra, p-WOX1 and JNK1 in SK-N-SH cells, as determined by pull-down analysis (Figure 7D). UV light increased the binding of endogenous Zfra with phosphorylated JNK1 (at Thr183/Tyr185) in SK-N-SH cells, as determined by co-immunoprecipitation (Figure 7E).
###end p 40
###begin title 41
Transiently overexpressed Zfra sequesters WOX1, NF-kappaB, p53 and p-ERK in the cytoplasm
###end title 41
###begin p 42
###xml 576 578 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8A</xref>
###xml 720 722 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8A</xref>
###xml 871 873 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8B</xref>
###xml 1022 1024 1006 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8C</xref>
The above data show that endogenous Zfra may physically interacts with endogenous WOX1, NF-kappaB and JNK1/2 in non-stimulated cells. We examined whether transiently overexpressed Zfra sequesters these proteins in the cytoplasm and prevents their nuclear translocation by stress stimuli. SK-N-SH cells were electroporated with EGFP-Zfra or EGFP only, followed by culturing for 24 hr. Transiently overexpressed EGFP-Zfra suppressed nuclear localization of NF-kappaB (p65), WOX1, p53, p-ERK (extracellular signal-regulated kinase), but had little or no effect on JNK1/2 (Figure 8A). TNF induced nuclear translocation of NF-kappaB in EGFP control cells, but this event was blocked in the EGFP-Zfra-expressing cells (Figure 8A). Similarly, in Zfra-negative breast MCF7 cells, transiently overexpressed EGFP-Zfra suppressed nuclear translocation of NF-kappaB and WOX1 (Figure 8B). Interestingly, transiently overexpressed EGFP-Zfra did not have a significant effect on the nuclear localization of WOX1 in Molt4 T cells (Figure 8C). However, EGFP-Zfra blocked UV light-induced WOX1 nuclear translocation in Molt4 T cells.
###end p 42
###begin p 43
###xml 0 87 0 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Transiently overexpressed Zfra sequesters NF-&#954;B, WOX1, p53 and ERK in the cytoplasm</bold>
###xml 287 291 283 287 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A, B</bold>
###xml 295 296 291 292 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 660 661 648 649 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 821 822 805 806 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
Transiently overexpressed Zfra sequesters NF-kappaB, WOX1, p53 and ERK in the cytoplasm. Breast MCF7 and neuroblastoma SK-N-SH cells were electroporated with an EGFP-Zfra construct or EGFP only, cultured overnight, and exposed to TNF for 40 min. Expression of GFP and GFP-Zfra is shown (A, B). (A) Without stimulation, EGFP-Zfra alone inhibited nuclear localization of NF-kappaB (p65), WOX1, p53 and p-ERK (Y204 phosphorylated) in SK-N-SH cells, whereas it had little or no effect on JNK1/2. TNF (50 ng/ml) could not induce nuclear translocation of endogenous JNK1/2, NF-kappaB (p65), p-ERK, p53 and WOX1 in Zfra-expressing cells during treatment for 40 min. (B) Similarly, in MCF7 cells, EGFP-Zfra suppressed nuclear localization of NF-kappaB and WOX1, and TNF could not induce nuclear translocation of these proteins. (C) EGFP-Zfra did not have a significant effect on the nuclear localization of WOX1 in Molt4 T cells; however, it blocked UV light-induced nuclear translocation of WOX1. Ectopic expression of EGFP and EGFP-Zfra in the above cells is shown in each panel. The levels of cytosolic alpha-tubulin are regarded as loading controls.
###end p 43
###begin title 44
Zfra counteracts the apoptotic function of WOX1
###end title 44
###begin p 45
###xml 262 263 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9A</xref>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9A</xref>
###xml 726 728 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9A</xref>
Next, we examined whether Zfra counteracts the apoptotic function of WOX1. L929 cells were transfected with an apoptosis-inducing amount of EGFP-WOX1, in the presence or absence of low doses of EGFP-Zfra by CaPO4. In parallel with the above observations (Figure 4), low doses of Zfra enhanced the growth of L929 cells during 24 and 48 hr in culture (Figure 9A; data not shown for 48 hr). Zfra counteracted WOX1-mediated growth suppression and death of L929 cells, as determined using crystal violet staining (Figure 9A). Similar results were observed by counting the number of apoptotic nuclei (stained with DAPI; data not shown). Protein expression of EGFP-WOX1 and EGFP-Zfra were examined by fluorescence microscopy (Figure 9A). WOX1 is shown in a perinuclear area, whereas Zfra is expressed in both cytoplasm and nucleus.
###end p 45
###begin p 46
###xml 0 56 0 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Zfra antagonizes the apoptotic function of WOX1 and JNK1</bold>
###xml 58 62 58 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 473 477 473 477 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
###xml 880 884 880 884 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C) </bold>
Zfra antagonizes the apoptotic function of WOX1 and JNK1. (A) L929 cells were transfected with a cytotoxic dose of EGFP-WOX1 in the presence or absence of low doses of EGFP-Zfra by CaPO4 (n = 8). The cells were cultured 24 and 48 hrs and stained with crystal violet. Zfra blocked WOX1-mediated growth suppression and death in 24 hr (data not shown for 48 hr). Expression of EGFP-tagged Zfra and WOX1 is shown, as determined by fluorescence microscopy (400x magnification). (B) Similarly, L929 cells were electroporated with WOX1 and/or Zfra, cultured 48 hr, and then processed for DNA fragmentation. An apoptosis-inducing amount of WOX1 and a non-apoptosis-inducing dose of Zfra were used. In a positive control, cells were treated with staurosporine (stauro; 500 nM) for 16 hr. In negative controls, cells were electroporated with medium or GFP vector only. ep, electroporation. (C) L929 cells were electroporated with an apoptosis-inducing amount of WOX1 and/or Zfra, or JNK1 (or medium only), and cultured for 24 and 48 hrs, respectively. Apoptosis occurred in 24 hr, as evidenced by increased percentages of cells in the subG1 phase from cell cycle analysis (data not shown for 48 hr). WOX1, JNK1, or Zfra alone suppressed cell growth, as indicated by reduced cell populations at the G1. However, both Zfra and WOX1 or JNK1 could not increase apoptosis in a synergistic manner. X-axis: DNA content; Y-axis: Cell numbers.
###end p 46
###begin p 47
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9B</xref>
Similarly, L929 cells were electroporated with WOX1 and/or Zfra. These cells were cultured for 24 hr, and then processed for DNA fragmentation in agarose gel electrophoresis. WOX1-induced apoptosis was blocked by a non-apoptotic dose of Zfra (Figure 9B).
###end p 47
###begin p 48
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9C</xref>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9C</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9C</xref>
Again, L929 cells were then electroporated with apoptosis-inducing amounts of WOX1 and/or Zfra, followed by culturing for 24 and 48 hr, and then processing for cell cycle analysis by FACS. WOX1 or Zfra alone induced growth suppression and apoptosis, as evidenced by increases in the SubG1 phase and decreases in the G1 phase of the cell cycle in cell populations post transfection for 24 hr (Figure 9C; data not shown for 48 hr). However, when in combination, Zfra and WOX1 failed to synergistically increase cell death (Figure 9C). Similar results were observed by testing Zfra with JNK1 (Figure 9C). Overall, Zfra physically interacts with WOX1 and JNK1, and may counteract the apoptotic function of these proteins under stress conditions.
###end p 48
###begin title 49
Phosphorylation at Tyr33 is essential for WOX1 to counteract Zfra-mediated apoptosis
###end title 49
###begin p 50
###xml 74 75 74 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 126 127 126 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9</xref>
###xml 225 228 225 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10A</xref>
###xml 329 332 329 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10A</xref>
###xml 380 381 380 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 436 439 436 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10A</xref>
###xml 516 519 516 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10B</xref>
Phosphorylation of WOX1 at Tyr33 is essential for its apoptotic function [8]. In parallel with the above observations (Figure 9), overexpressed WOX1 did not synergistically increase cell death with Zfra in COS7 cells (Figure 10A). Also, alteration of Tyr33 to Arg (Y33R) abolished the apoptosis-inducing activity of WOX1 (Figure 10A). This Y33R mutant could not bind Zfra (Figure 6), and did not affect Zfra-mediated cell death (Figure 10A). This relationship was further verified in breast MDA-MB-231 cells (Figure 10B).
###end p 50
###begin p 51
###xml 0 119 0 119 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Phosphorylation of WOX1 at Tyr33 is essential for its apoptotic function and for counteracting Zfra-mediated cell death</bold>
###xml 121 125 121 125 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 689 693 687 691 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
###xml 969 973 965 969 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C) </bold>
###xml 1028 1029 1024 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1101 1102 1097 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1515 1516 1508 1509 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
Phosphorylation of WOX1 at Tyr33 is essential for its apoptotic function and for counteracting Zfra-mediated cell death. (A) Transiently overexpressed EGFP-Zfra and EGFP-WOX1 induced death of COS7 fibroblasts (n = 8, mean +/- standard deviation). Zfra counteracted with WOX1 in causing cell death. Alteration of Tyr33 to Arg33 (Y33R) abolished the apoptosis-inducing activity of WOX1, and this mutant did not block Zfra-mediated cell death. Expression of EGFP-tagged Zfra, WOX1 and WOX1(Y33R) is shown in fluorescent micrographs (400x magnification). WOX1 is shown in the perinuclear area, whereas the Y33R mutant tends to aggregate in the nuclei. Zfra is expressed ubiquitously in cells. (B) Similar experiments were carried out in breast MDA-MB-231 cells. Again, Zfra and WOX1 did not increase cell death in a synergistic manner (n = 8, mean +/- standard deviation). The Y33R mutant lost its apoptotic function and had no apparent effect on Zfra-mediated cell death. (C) L929 cells were transfected with the SDR domain plus a C-terminal tail (SDR/C) or the SDR domain alone (tagged with ECFP at the N-terminus). These cells were cultured for 24 hr in the presence or absence of a synthetic full-length Zfra peptide (10 muM), and the extent of cell death was determined by crystal violet staining. Zfra enhanced cell death caused by SDR/C (n = 8, mean +/- standard deviation). SDR alone could not cause cell death, and Zfra did not increase the cell death. Protein expression of ECFP-SDR/C and ECFP-SDR is shown. (D) Constructs made for the above experiments are shown.
###end p 51
###begin p 52
###xml 43 44 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 83 86 83 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10C</xref>
###xml 409 412 408 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10C</xref>
###xml 526 529 525 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10C</xref>
###xml 697 698 696 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
We tested the function of SDR domain and a C-terminal tail (SDR/C) in WOX1 (Figure 10C). L929 cells were transfected with cDNA constructs for expressing SDR or SDR/C, followed by culturing for 24 hr in the presence or absence of a synthetic full-length Zfra peptide (10 muM). Transiently overexpressed SDR/C exerted cell death. Zfra peptide alone had no effect but enhanced cell death caused by SDR/C (Figure 10C). SDR alone could not cause cell death and Zfra and SDR, in combination, did not increase the cell death (Figure 10C). Together, these observations indicate a critical role of Tyr33 phosphorylation in WOX1 in causing cell death and interacting with Zfra. Also, when Zfra binds to the C-terminal SDR/C region, both Zfra and WOX1 may enhance cell death in a synergistic manner.
###end p 52
###begin p 53
###xml 234 237 234 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10D</xref>
Protein expression of ECFP-SDR/C and ECFP-SDR is shown. The extent of protein expression was in more than 70% of transfected cells, as determined by fluorescence microscopy. Constructs made for the above experiments are shown (Figure 10D).
###end p 53
###begin title 54
Phosphorylation of p53 at Ser46 is essential for counteracting Zfra-mediated apoptosis
###end title 54
###begin p 55
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11</xref>
###xml 167 168 167 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11</xref>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11</xref>
Similarly, overexpressed p53 and Zfra nullified each other's effect in inducing death of COS7 cells (Figure 11). Zfra(S8G) mutant lost its apoptotic function (Figures 2 and 11), and had no effect in counteracting p53-mediated cell death (Figure 11). Mutant p53(S46G) had a reduced activity in causing cell death, and interestingly this mutant also inhibited Zfra's apoptotic function (Fig. 11). The extent of protein expression was more than 70%, as determined by fluorescence microscopy.
###end p 55
###begin p 56
###xml 0 97 0 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Phosphorylation of p53 at serine 46 (S46) is essential for counteracting Zfra-mediated cell death</bold>
Phosphorylation of p53 at serine 46 (S46) is essential for counteracting Zfra-mediated cell death. COS7 cells were co-transfected with both p53 and/or Zfra by electroporation, followed by culturing for 24 hr and then determining the extent of cell death by staining with crystal violet. In addition, the cells were also introduced with mutants of p53 (S46) and/or Zfra(S8G). The results show that p53 and Zfra nullified each other's activity in causing cell death (n = 8, mean +/- standard deviation). The apoptotic function of both Zfra(S8G) and p53(S46G) was significantly reduced. S8G mutant had no effect in reducing p53-mediated cell death.
###end p 56
###begin title 57
Discussion and conclusion
###end title 57
###begin p 58
###xml 199 201 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F12">12</xref>
###xml 485 488 481 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F12">12A</xref>
###xml 663 665 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 666 668 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
In this study we have shown that the small size Zfra regulates TNF-mediated cell death via directly binding with TRADD, NF-kappaB, JNK1, p-ERK and WOX1, and indirectly with FADD, RIP and p53 (Figure 12). Upon binding with p55 TNF receptor (p55-TNFR), TNF engages in two signaling pathways for either protecting cells from death or committing cells to death. For initiating cell death, p55-TNFR recruits TRADD, FADD and RIP to generate a death-inducing signaling complex (DISC) (Figure 12A). Caspase 8 is then recruited to the DISC and becomes activated, followed by activating downstream caspases to induce apoptosis at both the mitochondrial and nuclear levels [16,17].
###end p 58
###begin p 59
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A schematic model of Zfra/WOX1 involvement in TNF signaling</bold>
###xml 154 158 154 158 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 959 963 959 963 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
###xml 1334 1340 1326 1332 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Step 1</bold>
###xml 1432 1438 1424 1430 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Step 2</bold>
###xml 1665 1671 1657 1663 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Step 3</bold>
###xml 1754 1760 1746 1752 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Step 4</bold>
###xml 1961 1973 1929 1941 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Step 5 and 6</bold>
###xml 2064 2065 2024 2025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 2254 2262 2206 2214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 2334 2339 2278 2283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
A schematic model of Zfra/WOX1 involvement in TNF signaling. TNF is able to initiate two counteractive pathways - one apoptotic and the other protective. (A) In the death pathway, binding of TNF to the cognate p55-TNF receptor (TNFR) results in recruitment of death domain proteins TRADD, FADD and RIP, thus generating the so called death-inducing signaling complex (DISC). Caspase 8 and downstream effectors are then activated to induce cell death at the mitochondrial and nuclear levels [16,17]. In this study, we discovered that Zfra physically interacts with TRADD and WOX1, and that WOX1 binds TRADD. Thus, Zfra and WOX1 are likely to be recruited to the DISC. WOX1 enhances TNF cytotoxicity [3], and Zfra counteracts the WOX1 function. Zfra either enhances or inhibits the function of death domain proteins (open arrow). Thus, the ying and yang of cell death depends upon the strength of DISC formation and the counteractive or enhancing force of Zfra. (B) In the protective pathway, p55-TNF recruits TRADD, TRAF2 and RIP, followed by activating several downstream adaptors and finally JNK1 and NF-kappaB. We determined that overexpressed Zfra sequesters p53, WOX1, and NF-kappaB in the cytoplasm. Thus, Zfra is likely to bind and block the function of these proteins during TNF signaling (see each step marked by a number). In Step 1, at the membrane level, Zfra binds TRADD in the presence of TRADD, TRAF2, RIP and WOX1. In Step 2, a trimolecular complex of Zfra/JNK1/WOX1 may form when JNK1 is activated by the upstream activated MEK. Zfra binds and counteracts the apoptotic function of JNK1. Also, JNK1 counteracts the apoptotic function of WOX1 [6]. In Step 3, MEK activates ERK, and that Zfra may bind and sequester ERK to the cytoplasm. In Step 4, phosphorylation of IkappaBalpha by IKK causes degradation of IkappaBalpha and release of NF-kappaB for nuclear translocation. Again, Zfra is able to bind and sequester NF-kappaB in the cytoplasm. In Step 5 and 6, TNF induces NF-kappaB activation, and then NF-kappaB activates p53 [22]. The non-ankyrin C-terminus of IkappaBalpha physically interacts with cytosolic p53 [25]. p53 is functionally associated with WOX1, and both proteins may induce apoptosis synergistically [3,4,6,8]. Thus, an in vivo complex of Zfra with IkappaBalpha/p53/WOX1 or p53/WOX1 is likely (Chang et al., submitted).
###end p 59
###begin p 60
###xml 73 76 73 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F12">12A</xref>
###xml 344 347 344 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F12">12A</xref>
We determined that Zfra interacts with TRADD but not FADD or RIP (Figure 12A). Zfra affects the cytotoxic function of these death domain proteins via direct and indirect manners (open arrow). Zfra physically interacts with WOX1, and that WOX1 binds TRADD. Thus, Zfra and WOX1 are likely to be recruited to the DISC during TNF signaling (Figure 12A). This assumption has yet to be validated by co-immunoprecipitation and confocal and immunoelectron microscopy.
###end p 60
###begin p 61
###xml 62 63 62 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 118 119 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
Previously we have shown that WOX1 enhances TNF cytotoxicity [3]. WOX1 also enhances the cytotoxic function of TRADD [3]. Here we determined that both WOX1 and Zfra counteract with each other in regulating apoptosis. Zfra either enhances or inhibits the function of death domain proteins. Thus, the driving force for committing cells to death in response to TNF is likely coming from a balanced and counter-balanced work among Zfra, WOX1 and DISC.
###end p 61
###begin p 62
###xml 106 109 102 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F12">12B</xref>
###xml 217 223 213 219 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Step 1</bold>
###xml 315 321 311 317 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Step 2</bold>
###xml 546 547 542 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 553 559 549 555 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Step 3</bold>
###xml 642 648 638 644 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Step 4</bold>
###xml 849 861 821 833 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Step 5 and 6</bold>
###xml 910 911 882 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 912 914 884 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 915 917 887 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 988 990 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1009 1010 973 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1099 1106 1055 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1177 1179 1133 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1280 1281 1236 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1282 1283 1238 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1284 1285 1240 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1286 1287 1242 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1299 1307 1255 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1357 1362 1305 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 1657 1658 1605 1606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1659 1661 1607 1609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1662 1664 1610 1612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1849 1854 1789 1794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
In the TNF-initiated protective pathway, Zfra is shown to interact with TRADD, JNK1 and NF-kappaB (Figure 12B). Thus, formation of Zfra-containing regulatory complexes probably occurs in the TNF signaling cascade. In Step 1, at the membrane level, Zfra binds TRADD in the presence of TRADD, TRAF2, RIP and WOX1. In Step 2, a trimolecular complex of Zfra/JNK1/WOX1 may form when JNK1 becomes activated by the upstream activated MEK. Zfra binds and counteracts the apoptotic function of JNK1. Also, JNK1 counteracts the apoptotic function of WOX1 [6]. In Step 3, MEK activates ERK, and that Zfra may bind and sequester ERK to the cytoplasm. In Step 4, phosphorylation of IkappaBalpha by IKK causes degradation of IkappaBalpha and release of NF-kappaB for nuclear translocation. Again, Zfra is able to bind and sequester NF-kappaB in the cytoplasm. In Step 5 and 6, p53 is a downstream effector of TNF signaling [8,22-24]. TNF induces NF-kappaB activation, and then NF-kappaB activates p53 [22]. The non-ankyrin C-terminus of IkappaBalpha physically interacts with cytosolic p53 to prevent degradation in vivo, and the complex dissociates in response to TNF and apoptotic stress [25]. p53 is functionally associated with WOX1, and both proteins may induce apoptosis synergistically [3,4,6,8]. Thus, an in vivo complex of IkappaBalpha/p53/WOX1 is likely (Chang et al., submitted), and that Zfra may regulate the formation of this complex. We show that ectopic Zfra blocks UV light-induced p53 nuclear translocation or activation, suggesting a negative regulation for the cell death event. Ser46-phosphorylated p53 is known to play a critical role in apoptosis [8,25-29]. That is, Zfra may prevent cell death by blocking the apoptotic function of Ser46-phosphorylated p53. The IkappaBalpha/p53/WOX1 or p53/WOX1 may translocate to the mitochondria (Chang et al., submitted). Whether this event is blocked by Zfra is unknown.
###end p 62
###begin p 63
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 368 373 368 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vivo </italic>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1055 1057 1055 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1233 1235 1233 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1236 1238 1236 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1375 1377 1375 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1378 1380 1378 1380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
Presence of two cysteine residues in the amino acid sequence of Zfra suggests the likely presence of a dimeric form in cells [10]. Also, whether Zfra covalently interacts with specific proteins remains to be established. As determined by GST-pull down analysis, both TNF and UV light are able to increase self-association of Zfra, supporting the presence of dimers in vivo [10]. Zfra is inducible under stress conditions [10]. We show that at low levels Zfra enhances cell growth, and yet overexpressed Zfra induces cell death. Ectopic Zfra also blocked adherence-independent growth of L929 fibroblasts, suggesting that it may act as a tumor suppressor to block cancer growth and progression. Zfra is most abundant in the spleen, whereas its role in regulating immune cell differentiation and functions is unknown. However, it is reasonable to suggest that Zfra-regulated TNF signaling is likely to play a role in the lymphocyte differentiation. We also determined that absent expression of Zfra is found in several breast and prostate cancer cell lines [10], implying that Zfra deficiency may provide a growth advantage for cancer cells. Majority of zinc finger proteins participate in gene transcription and embryonic development [30-32]. Synthetic peptides have been shown promises in therapy to modulate the transcriptional activities of endogenous zinc finger proteins [33,34]. Shortening and/or modification of the naturally occurring Zfra may be of therapeutic value in controlling cancer cell growth and death.
###end p 63
###begin p 64
###xml 419 420 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 444 445 440 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
Zfra is distributed ubiquitously in cellular compartments. In response to TNF, a portion of cytosolic Zfra appears to translocate to the cell membrane area and binds TRADD. Death domain/death domain interaction is responsible for TRADD binding with p55-TNFR, FADD and RIP. Whether Zfra binds to the death domain is unknown. Sequence alignment analysis shows a common structural motif in TRADD, JNK1, NF-kappaB, and the N-terminal WW domain and C-terminal SDR domain of WOX1. Whether this motif interacts with Zfra remains to be established.
###end p 64
###begin p 65
###xml 74 75 70 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 76 77 72 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 78 80 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 81 83 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 152 160 148 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 164 173 160 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 301 302 297 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 303 304 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 305 306 301 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 307 308 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 309 311 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 312 314 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 371 372 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 399 400 395 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 666 668 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 669 671 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 815 817 811 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 901 912 897 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 913 915 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 973 981 969 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 982 983 978 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 249 258 <span type="species:ncbi:10090">nude mice</span>
###xml 901 911 <span type="species:ncbi:7227">Drosophila</span>
WWOX/WOX1 is known to interact with p53, p73, JNK1, AP-2gamma, and ErbB4 [3,6,35-37], suggesting its role of the regulation of gene transcription. Both in vivo and in vitro studies have shown that overexpressed WWOX1/WOX1 suppresses tumor growth in nude mice, and induces apoptosis in cultured cells [3,6,8,9,38,39]. Overexpressed WW and SDR/C domains induce cell death [3]. Most interestingly, the C-terminal tail of WOX1 is needed to work together with SDR in causing cell death. In stark contrast, non-invasive breast and prostate cancers may have upregulated expression of WWOX/WOX1, Tyr33 phosphorylation and WWOXv2/WOX2 (and other family proteins if present) [40-42]. Downregulation of WOX1 and WOX2 promotes neurodegeneration in Alzheimer's disease, suggesting its protective role against neurodegeneration [43]. FOR (WWOX/WOX1) is shown to protect against the effects of ionizing radiation in Drosophila [44]. These observations support a pro-survival role of WOX1 in vivo [4].
###end p 65
###begin p 66
###xml 82 83 82 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 236 237 236 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 637 642 637 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 750 751 750 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 28 33 <span type="species:ncbi:4932">yeast</span>
In domain/domain mapping by yeast two-hybrid analysis, Zfra was shown to bind the N-terminal Tyr33-phosphorylated WW domain of WOX1. Alteration of this phosphorylation site abolishes the binding interaction. Also, it interacts with the C-terminal SDR domain of WOX1. Since Zfra is a small peptide, its simultaneous binding to these domains in WOX1 under physiologic and stress conditions is very likely. Our supporting evidence shows that stress stimuli induce phosphorylation of WOX1 at Tyr33 and Zfra at Ser8, and that the Zfra/WOX1 complex co-translocates to the mitochondria to regulate cell death via the mitochondrial pathway (Hsu et al., submitted). Also, in this study we found that Zfra enhances the apoptotic activity of SDR domain and the C-terminal tail of WOX1.
###end p 66
###begin p 67
Overexpressed Zfra may nullify the apoptotic activities of WOX1 and p53. An apparent mechanism is that overexpressed Zfra sequesters transcriptional factors in the cytoplasm. For example, ectopic Zfra restricts nuclear localization of endogenous WOX1, p53, ERK, and NF-kappaB (p65), indicating that an upregulated level of Zfra may control the transcriptional system in cells under stress conditions.
###end p 67
###begin p 68
Taken together, we have identified a molecular pathway underlying Zfra regulation of TNF cytotoxic function. Zfra interacts with TRADD and binds downstream NF-kappaB, p53, JNK1 and WOX1 of the TNF signal pathway, thereby either enhancing or restricting TNF-mediated cell death.
###end p 68
###begin title 69
Methods
###end title 69
###begin title 70
Cell lines, antibodies and chemicals
###end title 70
###begin p 71
###xml 610 612 606 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NH</italic>
###xml 618 622 614 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COOH</italic>
###xml 692 693 688 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 694 695 690 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 696 698 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 699 701 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 728 730 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 759 761 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 49 55 <span type="species:ncbi:10090">murine</span>
###xml 109 114 <span type="species:ncbi:9606">human</span>
###xml 276 281 <span type="species:ncbi:9606">human</span>
###xml 314 319 <span type="species:ncbi:9606">human</span>
###xml 344 349 <span type="species:ncbi:9606">human</span>
###xml 387 392 <span type="species:ncbi:9606">human</span>
###xml 434 439 <span type="species:ncbi:9606">human</span>
###xml 469 473 <span type="species:ncbi:452646|species:ncbi:9666">mink</span>
Majority of our experiments were performed using murine L929 fibroblasts, monkey kidney COS7 fibroblasts and human Molt4 T lymphocytes for ectopic gene expression. In addition, the following cell lines were cultured and tested for their sensitivity to Zfra-mediated death: 1) human neuroblastoma SK-N-SH cells, 2) human ovarian ME180 cells, 3) human breast MDA-MB-231 and MCF7 cells, 4) human embryonic kidney HEK-293 fibroblasts, 5) human prostate DU145 cells, and 6) mink lung epithelial Mv1Lu cells. Recombinant TNF-alpha was from PeproTech and R&D Systems. We have produced specific antibodies against the NH- and COOH-termini of WOX1, recombinant GST-WOX1 and Tyr33-phosphorylated WOX1 [3,6,43,45], synthetic Zfra peptide [10], and recombinant GST-Zfra [10]. The following specific antibodies were from Santa Cruz Biotechnology: p-JNK1 (phospho-JNK1 at Thr183/Tyr185), WWOX, NF-kappaB, IkappaBalpha, FADD, and p53. Anti-WWOX IgG, N-19 and P-20, were kind gifts of Santa Cruz Biotechnology. alpha-Tubulin antiserum was from Accurate Chemical, and anti-RIP from Pharmingen/BD Biosciences.
###end p 71
###begin title 72
Zfra and WOX1 cDNA constructs and transient gene expression
###end title 72
###begin p 73
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 252 253 252 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 325 326 325 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 327 328 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 424 425 420 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 591 592 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 593 594 589 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 595 596 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 597 599 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 600 602 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 800 801 796 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1058 1059 1054 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1060 1061 1056 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1062 1063 1058 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1064 1066 1060 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 24 27 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 168 174 <span type="species:ncbi:10090">Murine</span>
###xml 334 339 <span type="species:ncbi:9606">Human</span>
Zfra was constructed in CMV-based mammalian expression vectors pCR3.1 (Invitrogen) and pEGFPC1 (enhanced green fluorescent protein; cloning site EcoR1; Clontech) [10]. Murine full length WOX1, Y33R mutant, WW domains, SDR domain, and SDR domain with a C-terminal tail were constructed in pCR3.1, pEGFPC1 and pECFGC1 vectors [3,6,43]. Human p53 and p53(DeltaS46) cDNAs were constructed in pDsRed-N1 (Clontech), as described [8]. Where indicated, cell lines were transfected with Zfra, WOX1 or p53 constructs, or empty vectors (15-600 ng/well) by calcium phosphate (CaPO4) or electroporation [3,6,8,10,43]. In electroporation, cells were transfected with the indicated expression constructs in the presence of albumin to enhance gene expression and reduce electric shock-induced accidental cell death [8]. Post transfection for 24-48 hr, the extent of cell growth or death was examined by crystal violet staining, cell cycle analysis by propidium iodide staining and fluorescence activated cell sorting (FACS), Annexin V assay, and DNA fragmentation analyses [3,6,8,43].
###end p 73
###begin title 74
Site-directed mutagenesis
###end title 74
###begin p 75
The conserved phosphorylation site Ser8 in Zfra was mutated using QuikChange site-directed mutagenesis Kit (Stratagene). PCR primers for S8G-Zfra mutant were designed as follows: 1) S8G forward, GCAGAAGGTCGTCTGGCTGTAAATATTGTGA; 2) S8G reverse, TCACAATATTTACAGCCAGACGACCTTCTGC.
###end p 75
###begin title 76
Soft agarose colony survival assay
###end title 76
###begin p 77
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 251 253 251 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 594 596 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 308 314 <span type="species:ncbi:9913">bovine</span>
Adherence-independent or transforming cell growth was performed in a soft agarose colony survival assay [21]. Briefly, L929 cells were electroporated with expression constructs of EGFP-Zfra or EGFP alone. These cells were plated at a density of 3 x 104 cells/35-mm dish in triplicate in RPMI 1640, 10% fetal bovine serum, 0.8% agarose, and 10 mM Hepes. Dishes were incubated in a humidified CO2 incubator at 37degreesC for 3 weeks. The resulting colonies were stained with a soluble tetrazolium-based MTS cell proliferation reagent (Promega), and live colonies (with brown color) were counted [21].
###end p 77
###begin title 78
Electroporation, immunoprecipitation, and GST-Zfra pull-down assays
###end title 78
###begin p 79
###xml 162 164 160 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 247 248 245 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 249 250 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 251 252 249 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 253 255 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 616 617 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 618 619 612 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 620 621 614 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 622 624 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 887 888 881 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 889 890 883 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 891 892 885 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 893 895 887 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 896 898 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 73 79 <span type="species:ncbi:9913">bovine</span>
Cells were suspended in serum-free culture medium, containing 500 mug/ml bovine albumin, and electroporated with an EGFP-Zfra or EGFP construct (20 mug DNA/3 x 106 cells; 180 volt and 50 msec; BTX ECM 830 Square Wave Electroporator; Genetronics) [3,6,8,43]. Albumin enhanced both the transfection efficiency and gene expression by 3-5 folds. These cells were cultured 24-48 hr and then exposed to UV light or TNF-alpha for indicated times. Cytosolic and nuclear protein fractions were prepared using an NE-PER nuclear and cytosolic extraction kit (Pierce), followed by quantification, SDS-PAGE and Western blotting [3,6,8,43]. Where indicated, we performed 1) immunoprecipitation using specific antibodies against Zfra, and 2) pull-down assays using glutathione-Sepharose 4B beads coated with GST (Glutathione S-Transferase) or GST-Zfra to examine the presence of Zfra-binding proteins [3,6,8,10,43].
###end p 79
###begin title 80
###xml 12 17 <span type="species:ncbi:4932">yeast</span>
Cytoplasmic yeast two-hybrid analysis
###end title 80
###begin p 81
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 98 99 98 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 332 339 332 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdc25H </italic>
###xml 763 764 751 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 765 766 753 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 767 768 755 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1087 1088 1075 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1089 1090 1077 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1091 1092 1079 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 17 22 <span type="species:ncbi:4932">yeast</span>
###xml 302 307 <span type="species:ncbi:4932">yeast</span>
###xml 326 331 <span type="species:ncbi:4932">yeast</span>
###xml 432 437 <span type="species:ncbi:4932">yeast</span>
###xml 532 538 <span type="species:ncbi:10090">murine</span>
###xml 1051 1056 <span type="species:ncbi:9606">human</span>
Ras rescue-based yeast two-hybrid analysis (CytoTrap, Stratagene) was performed as described [3,6,8]. Briefly, a cytosolic Sos-tagged bait protein is designed for binding to a cell membrane-anchored target protein (tagged with a myristoylation signal). This binding activates the Ras signal pathway in yeast and allows mutant yeast cdc25H to grow at 37degreesC using a selective agarose plate containing galactose. Without binding, yeast cells cannot grow at 37degreesC. We made the following bait constructs (in pSos vector): 1) a murine full-length WOX1, 2) the first WW domain and an NH2-terminal WW domain area of WOX1, 3) a COOH-terminal SDR domain area of WOX1 and a mitochondria-targeting region in this domain, and 4) a Y33R mutant in the WW domain area [3,6,8]. For target, a construct for Zfra was made in pMyr vector. Where indicated, full-length TRADD and RIP cDNAs were subcloned in pMyr (as target) or pSos (as bait). TRADD and RIP cDNAs were gifts of Dr. D. Goedell of Tularik/Amgen. Control constructs for the binding experiments were human MafB (in both pMyr and pSos) [3,6,8].
###end p 81
###begin title 82
Authors' contributions
###end title 82
###begin p 83
QH carried out molecular analysis of protein/protein interactions. LJH performed protein-binding interactions and manuscript preparation. LS participated in preparing DNA expression constructs, cell growth and death assays, and necessary reagents for experiments. NP and JM participated in preparing constructs. NSC conceived of the study and experimental design, carried out key experiments, and wrote the manuscript. QH, LJH and NSC read and approved the final manuscript.
###end p 83
###begin title 84
Acknowledgements
###end title 84
###begin p 85
Research was supported in part by the American Heart Association, the Department of Defense (DAMD17-03-1-0736), the Guthrie Foundation for Education and Research, and the National Science Council, Taiwan, ROC (NSC96-2320-B-006-014-) (to NSC). LJH was supported by grants from the Ministry of Education (91-B-FA09-1-4) and National Science Council, Taiwan (NSC 95-2320-B-006-072-MY2).
###end p 85
###begin article-title 86
###xml 54 59 <span type="species:ncbi:9606">human</span>
WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer
###end article-title 86
###begin article-title 87
Common chromosomal fragile site FRAD16D sequence: identification of the FOR gene spanning FRAD16D and homozygous deletions and translcoation breakpoints in cancer cells
###end article-title 87
###begin article-title 88
Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity
###end article-title 88
###begin article-title 89
WW domain-containing oxidoreductase: a candidate tumor suppressor
###end article-title 89
###begin article-title 90
Large common fragile site genes and cancer
###end article-title 90
###begin article-title 91
JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis
###end article-title 91
###begin article-title 92
A potential role of p53 and WOX1 in mitochondrial apoptosis (review)
###end article-title 92
###begin article-title 93
WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53
###end article-title 93
###begin article-title 94
Light-induced retinal damage involves tyrosine 33 phosphorylation
###end article-title 94
###begin article-title 95
Cloning and characterization of a small-size peptide Zfra that regulates the cytotoxic function of tumor necrosis factor by interacting with JNK1
###end article-title 95
###begin article-title 96
Three classes of C2H2 zinc finger proteins
###end article-title 96
###begin article-title 97
Zinc finger proteins: getting a grip on RNA
###end article-title 97
###begin article-title 98
Multiple modes of RNA recognition by zinc finger proteins
###end article-title 98
###begin article-title 99
Cloning and analysis of a FoxO transcription factor from Xiphophorus
###end article-title 99
###begin article-title 100
Damage of zinc fingers in DNA repair proteins, a novel molecular mechanism in carcinogenesis
###end article-title 100
###begin article-title 101
Modulation of life and death by the tumor necrosis factor receptor-associated factors (TRAFs)
###end article-title 101
###begin article-title 102
Tumor necrosis factor ligand-receptor superfamily and arthritis
###end article-title 102
###begin article-title 103
Signal transduction by tumor necrosis factor mediated by JNK protein kinases
###end article-title 103
###begin article-title 104
c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor alpha-induced c-Jun kinase activation and apoptosis
###end article-title 104
###begin article-title 105
JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species
###end article-title 105
###begin article-title 106
TIAF1 and p53 functionally interact in mediating apoptosis and silencing of TIAF1 abolishes nuclear translocation of serine 15-phosphorylated p53
###end article-title 106
###begin article-title 107
NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress
###end article-title 107
###begin article-title 108
###xml 123 128 <span type="species:ncbi:9606">human</span>
Tumor suppressor p53 as a component of the tumor necrosis factor-induced, protein kinase PKR-mediated apoptotic pathway in human promonocytic U937 cells
###end article-title 108
###begin article-title 109
p53 and Nur77/TR3 - transcription factors that directly target mitochondria for cell death induction
###end article-title 109
###begin article-title 110
The non-ankyrin C terminus of IkBa physically interacts with p53 in vivo and dissociates in response to apoptotic stress, hypoxia, DNA damage, and transforming growth factor-beta 1-mediated growth suppression
###end article-title 110
###begin article-title 111
p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53
###end article-title 111
###begin article-title 112
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis
###end article-title 112
###begin article-title 113
Nitric oxide prevents UV-induced phosphorylation of the p53 tumor-suppressor protein at serine 46: a possible role in inhibition of apoptosis
###end article-title 113
###begin article-title 114
###xml 19 24 <span type="species:ncbi:9606">human</span>
Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified
###end article-title 114
###begin article-title 115
A novel subfamily of zinc finger genes involved in embryonic development
###end article-title 115
###begin article-title 116
The ZIC gene family in development and disease
###end article-title 116
###begin article-title 117
Survey of microarray technologies suitable to elucidate transcriptional networks as exemplified by studying KRAB zinc finger gene families
###end article-title 117
###begin article-title 118
Artificial zinc finger peptides: creation, DNA recognition, and gene regulation
###end article-title 118
###begin article-title 119
Designer zinc-finger proteins and their applications
###end article-title 119
###begin article-title 120
Functional association between Wwox tumor suppressor protein and p73, a p53 homolog
###end article-title 120
###begin article-title 121
Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor
###end article-title 121
###begin article-title 122
WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function
###end article-title 122
###begin article-title 123
WWOX gene restoration prevents lung cancer growth in vitro and in vivo
###end article-title 123
###begin article-title 124
WOX1 is essential for UVB irradiation-induced apoptosis and down-regulated via translational blockade in UVB-induced cutaneous squamous cell carcinoma in vivo
###end article-title 124
###begin article-title 125
An opposing view on WWOX protein function as a tumor suppressor
###end article-title 125
###begin article-title 126
17beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo
###end article-title 126
###begin article-title 127
A role for the WWOX gene in prostate cancer
###end article-title 127
###begin article-title 128
Downregulation of WOX1 induces Tau phosphorylation in vitro: A potential role in Alzheimer's disease
###end article-title 128
###begin article-title 129
###xml 120 130 120 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 120 130 <span type="species:ncbi:7227">Drosophila</span>
FRA16D common chromosomal fragile site oxido-reductase (FOR/WWOX) protects against the effects of ionizing radiation in Drosophila
###end article-title 129
###begin article-title 130
###xml 73 79 <span type="species:ncbi:10090">murine</span>
Expression of WW domain-containing oxidoreductase WOX1 in the developing murine nervous system
###end article-title 130

